| Ytd | -13.37% | |
| 1y | -12.94% |
| Open | 1.90 | Prev Close | 1.86 | Low | 1.75 | High | 1.95 | Mkt Cap | 241.65M |
| Vol | 1.66M | Avg Vol | 903.21K | EPS | -0.49 | P/E | N/A | Forward P/E | -5.68 |
| Beta | 0.25 | Short Ratio | 0.31 | Inst. Own | 24.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.59 | 200-d Avg | 1.89 | 1yr Est | 8.00 |
PRQR News
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a
Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowe
ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concur
ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedi
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (N